.

Deeper Knowledge, Faster

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
Moodys
Colorcon
Argus Health
Healthtrust
AstraZeneca
Medtronic
Citi
US Army
Farmers Insurance

Generated: November 18, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 019129

« Back to Dashboard
NDA 019129 describes MAXZIDE-25, which is a drug marketed by Mylan Pharms Inc and is included in one NDA. It is available from eight suppliers. Additional details are available on the MAXZIDE-25 profile page.

The generic ingredient in MAXZIDE-25 is hydrochlorothiazide; triamterene. There are thirty-one drug master file entries for this compound. Forty suppliers are listed for this compound. Additional details are available on the hydrochlorothiazide; triamterene profile page.

Summary for 019129

Tradename:
2
Applicant:
1
Ingredient:
1
Patents:0
Formulation / Manufacturing:see details

Pharmacology for NDA: 019129

Suppliers and Packaging for NDA: 019129

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
MAXZIDE
hydrochlorothiazide; triamterene
TABLET;ORAL 019129 NDA Mylan Pharmaceuticals Inc. 0378-0460 0378-0460-01 100 TABLET in 1 BOTTLE, PLASTIC (0378-0460-01)
MAXZIDE
hydrochlorothiazide; triamterene
TABLET;ORAL 019129 NDA Mylan Pharmaceuticals Inc. 0378-0464 0378-0464-01 100 TABLET in 1 BOTTLE, PLASTIC (0378-0464-01)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength50MG;75MG
Approval Date:Oct 22, 1984TE:ABRLD:Yes

Summary for product number 003

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength25MG;37.5MG
Approval Date:May 13, 1988TE:ABRLD:Yes

Expired Orange Book Patents for NDA: 019129

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Mylan Pharms Inc
MAXZIDE
hydrochlorothiazide; triamterene
TABLET;ORAL019129-001Oct 22, 1984► Subscribe► Subscribe
Mylan Pharms Inc
MAXZIDE-25
hydrochlorothiazide; triamterene
TABLET;ORAL019129-003May 13, 1988► Subscribe► Subscribe
Mylan Pharms Inc
MAXZIDE
hydrochlorothiazide; triamterene
TABLET;ORAL019129-001Oct 22, 1984► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.



Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

US Department of Justice
Merck
Baxter
UBS
Fish and Richardson
Harvard Business School
Deloitte
Cipla
Chinese Patent Office
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot